The overall prognosis in patients who attain pathologic complete response (pCR) is exceptional5 and the highest pCR rates are observed in patients with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2)-positive subtypes; in whom the association between pCR and improved outcomes is also strongest5,6. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.